Ignite Creation Date:
2024-05-06 @ 7:25 PM
Last Modification Date:
2024-10-26 @ 3:06 PM
Study NCT ID:
NCT06001658
Status:
RECRUITING
Last Update Posted:
2024-06-26
First Post:
2023-08-08
Brief Title:
Perioperative Gemcitabine Cisplatin and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
Tumor Microenvironment Features of Response to Perioperative Gemcitabine Cisplatin and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety of peri-operative gemcitabine cisplatin and pembrolizumab in patients with BTC as well as whether the combination of gemcitabine cisplatin and pembrolizumab gemcispembro is feasible and lead to pathologic responses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IRB00371087 | OTHER | Johns Hopkins Medicine Internal Review Board | None |